RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework
暂无分享,去创建一个
[1] A. Slade,et al. Patient reported outcome measures in rare diseases: a narrative review , 2018, Orphanet Journal of Rare Diseases.
[2] P. Clifton,et al. Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration , 2017, Journal of atherosclerosis and thrombosis.
[3] M. Bellgard,et al. Research protocol: The initiation, design and establishment of the Global Angelman Syndrome Registry , 2018, Journal of intellectual disability research : JIDR.
[4] N. Zeps,et al. Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model , 2018, Blood cells, molecules & diseases.
[5] Christophe Béroud,et al. Dispelling myths about rare disease registry system development , 2013, Source Code for Biology and Medicine.
[6] Finding Benefit in n-of-1 Trials. , 2019, JAMA internal medicine.
[7] Christopher H Schmid,et al. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. , 2010, Journal of clinical epidemiology.
[8] F. Bianchi,et al. Recommendations for Improving the Quality of Rare Disease Registries , 2018, International journal of environmental research and public health.
[9] M. Bellgard,et al. The role of patient registries for rare genetic lipid disorders , 2018, Current opinion in lipidology.
[10] Matthew I. Bellgard,et al. Rare Disease Research Roadmap: Navigating the bioinformatics and translational challenges for improved patient health outcomes , 2014 .
[11] Christopher H. Schmid,et al. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. , 2013, Journal of clinical epidemiology.
[12] S. Cano,et al. Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures , 2017, Orphanet Journal of Rare Diseases.
[13] N. Dreyer,et al. Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .
[14] M. Bellgard,et al. A web-based, patient driven registry for Angelman syndrome: the global Angelman syndrome registry , 2017, Orphanet Journal of Rare Diseases.
[15] G. Watts,et al. A Web-Based Registry for Familial Hypercholesterolaemia. , 2017, Heart, lung & circulation.
[16] J. Nikles,et al. A series of N-of-1 trials to assess the therapeutic interchangeability of two enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study protocol for a randomized controlled trial , 2017, Trials.
[17] Lee Render,et al. A Registry Framework Enabling Patient-Centred Care. , 2015, Studies in health technology and informatics.
[18] Erik Schultes,et al. The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.
[19] S. Berry,et al. Efficiencies of platform clinical trials: A vision of the future , 2016, Clinical trials.
[20] J. McNeil,et al. Rare disease registries: a call to action , 2017, Internal medicine journal.
[21] Adam Hunter,et al. A modular approach to disease registry design: Successful adoption of an internet‐based rare disease registry , 2012, Human mutation.
[22] J. Nikles,et al. The Essential Guide to N-of-1 Trials in Health , 2015, Springer Netherlands.
[23] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[24] Adam Hunter,et al. Second generation registry framework , 2014, Source Code for Biology and Medicine.
[25] J. Connor,et al. The platform trial: an efficient strategy for evaluating multiple treatments. , 2015, JAMA.
[26] Martin Frank,et al. Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems , 2015, The European Journal of Health Economics.
[27] K. Bushby,et al. Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database , 2017, Journal of neuromuscular diseases.